middle.news
How Anatara Lifesciences Navigates Mixed GaRP-IBS Trial Results and Patent Wins
9:25am on Tuesday 29th of July, 2025 AEST
•
Healthcare
Read Story
How Anatara Lifesciences Navigates Mixed GaRP-IBS Trial Results and Patent Wins
9:25am on Tuesday 29th of July, 2025 AEST
Key Points
Phase II GaRP-IBS trial safe but primary efficacy endpoint unmet
Secondary endpoints including anxiety improvement reached statistical significance
GaRP patents granted in Hong Kong and Japan, expanding IP protection
Anti-Obesity pre-clinical studies progress to treatment challenge phase
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anatara Lifesciences (ASX:ANR)
OPEN ARTICLE